# RM-1995 Photoimmunotherapy, as Monotherapy or Combined With Pembrolizumab, in Patients With Advanced CuSCC and HNSCC

> **NCT05220748** · PHASE1 · WITHDRAWN · sponsor: **Rakuten Medical, Inc.**

## Conditions studied

- Cutaneous Squamous Cell Carcinoma
- Head and Neck Squamous Cell Carcinoma

## Interventions

- **COMBINATION_PRODUCT:** RM-1995
- **BIOLOGICAL:** Pembrolizumab

## Key facts

- **NCT ID:** NCT05220748
- **Lead sponsor:** Rakuten Medical, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-03-24
- **Primary completion:** 2023-01-30
- **Final completion:** 2023-01-30
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Decision was made due to a strategic re-evaluation of pipelines; no patients were enrolled.
- **Last updated:** 2023-04-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05220748

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05220748, "RM-1995 Photoimmunotherapy, as Monotherapy or Combined With Pembrolizumab, in Patients With Advanced CuSCC and HNSCC". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05220748. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*